Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 77

Sort by

Sort Order Select

Journal Articles

Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients

Diletta Fontana, PhD, Daniele Ramazzotti, PhD, Andrea Aroldi, MD, Antonio Niro, MS, Luca Massimino, PhD, Delphine Rea, MD, Fabio Stagno, MD, Bruno Martino, MD, Leonardo Campiotti, MD, Giovanni Caocci, MD, Elena Maria Elli, MD, Monica Fumagalli, MD, Fabio Ciceri, MD, Rocco Piazza, MD PhD, Carlo Gambacorti-Passerini, MD

Blood (2019) 134 (Supplement_1): 1714.

https://doi.org/10.1182/blood-2019-126467

Published: 2019

Journal Articles

Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome

Koji Sasaki, MD, Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Elias Jabbour, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Kiran Naqvi, MDMPH, Naval G. Daver, MD, Sherry A. Pierce, BSN, BA, Koichi Takahashi, MD, Courtney D. DiNardo, MDMSc, Graciela M. Nogueras González, MPH, Keyur Patel, MD PhD, Kelly Soltysiak, PhD, Junya Sato, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 1720.

https://doi.org/10.1182/blood-2019-130155

Published: 2019

Journal Articles

US Optum Database Study in Polycythemia Vera Patients: Thromboembolic Events (TEs) with Hydroxyurea (HU) Vs Ruxolitinib Switch Therapy and Machine-Learning Model to Predict Incidence of Tes and HU Failure

Srdan Verstovsek, MD PhD, Valerio De Stefano, MD, Florian H. Heidel, MD, Mike Zuurman, PhD, Michael Zaiac, MD, Erwan Bigan, PhD, Michael Ruhl, PhD, Christoph Meier, PhD, Magali Beffy, PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2019) 134 (Supplement_1): 1659.

https://doi.org/10.1182/blood-2019-126410

Published: 2019

Journal Articles

Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)

Nathan Radakovich, BA, Mikkael A. Sekeres, MD MS, Cameron Beau Hilton, BA, Sudipto Mukherjee, MD PhD MPH, Jacob Shreve, MD MS, Yazan Rouphail, Rachel Shirley, Vera Adema, PhD, Hassan Awada, MD, Anjali S. Advani, MD, Cassandra M Kerr, MS, Yasunobu Nagata, MD PhD, Yihong Guan, PhD, Teodora Kuzmanovic, BA, Metis Hasipek, PhD, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD, Aziz Nazha, MD

Blood (2019) 134 (Supplement_1): 2089.

https://doi.org/10.1182/blood-2019-126275

Published: 2019

Journal Articles

Supervised Machine Learning Algorithms Using Patient Related Factors to Predict in-Hospital Mortality Following Acute Myeloid Leukemia Therapy

Nauman Saleem Siddiqui, MD, Andreas Klein, MD, Amandeep Godara, MD, Cindy Varga, MD BSc, Rachel J. Buchsbaum, MD, Michael C. Hughes, PhD

Blood (2019) 134 (Supplement_1): 3435.

https://doi.org/10.1182/blood-2019-128823

Published: 2019

Journal Articles

Cost-Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease

Lee F. Allen, MD PhD, Kavita Aggarwal, PharmD, Michael Vredenburg, PhD, Christine Barnett, PhD, Deirdre Mladsi, BA, Ray Kim, MD

Blood (2019) 134 (Supplement_1): 3454.

https://doi.org/10.1182/blood-2019-131822

Published: 2019

Journal Articles

BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

Georgina S. Daher-Reyes, MD, Isabelle Bence-Bruckler, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Mary-Margaret Keating, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 2933.

https://doi.org/10.1182/blood-2019-131454

Published: 2019

Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Cynthia Z. Qi, MBA, Bhavik J. Pandya, PharmD, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 3859.

https://doi.org/10.1182/blood-2019-123819

Published: 2019

Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Bhavik J. Pandya, PharmD, Cynthia Z. Qi, MBA, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 5085.

https://doi.org/10.1182/blood-2019-123811

Published: 2019

Journal Articles

Beyond the Routine CBC: Research CBC Parameters Associated with Myelodysplastic Syndromes and Underlying Mutations

Olga Pozdnyakova, MD PhD, Radu Stefan Niculescu, PhD, Tracey Kroll, BSc, Lisa Golemme, MLS (ASCP), MS, Nolan Raymond, MLS (ASCP), Debra Briggs, MT(ASCP), MS, Annette S. Kim, MD PhD

Blood (2019) 134 (Supplement_1): 5419.

https://doi.org/10.1182/blood-2019-125654

Published: 2019

Journal Articles

Dasatinib and Nilotinib As Upfront Therapy for Chronic-Phase Chronic Myeloid Leukemia (CML-CP) in Qatar: A Cost Effectiveness Analysis (CEA)

Ahmad M Adel, MSc, Dina Abushanab, MSc, Anas Hamad, PhD, Mohammad Abdul-Jaber Abdulla, MD, Mohamed A Yassin, MBBS, MSc

Blood (2019) 134 (Supplement_1): 5850.

https://doi.org/10.1182/blood-2019-121833

Published: 2019

Journal Articles

Is It Time to Take MRD More Seriously? Relationship between MRD, Functional Cure and Life Expectancy Among Patients with Ph- B Cell Precursor ALL (BCP-ALL)

Qiujun Shao, Simran Tiwana, Nicholas Despiegel, Franziska Dirnberger

Blood (2019) 134 (Supplement_1): 5814.

https://doi.org/10.1182/blood-2019-126309

Published: 2019

Journal Articles

Use of Machine Learning in 2074 Cases of Acute Myeloid Leukemia for Genetic Risk Profiling

Shaun Fleming, MBBS,, Cheng-Hong Tsai, MD MSc, Hartmut Döhner, MD, Konstanze Döhner, Elli Papaemmanuil, PhD, Hwei-Fang Tien, MD, PhD, John Reynolds, PhD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Hsin-An Hou

Blood (2019) 134 (Supplement_1): 1392.

https://doi.org/10.1182/blood-2019-128243

Published: 2019

Journal Articles

Dasatinib Inhibits FLT3 /ITD and PTPN11 mutated Acute Myeloid Leukemia Cells Overexpressing SRC Tyrosine Kinases

Sigal Tavor, MD, Tali Shalit, PhD, Noa Chapal Ilani, PhD, Yoni Moskovitz, PhD, Nir Livnat, BSc, Yoram Groner, PhD, Haim Bar, PhD, Alexander Plotnikov, PhD, Nathali Kaushansky, PhD, Liran I. Shlush, MD

Blood (2019) 134 (Supplement_1): 1451.

https://doi.org/10.1182/blood-2019-128016

Published: 2019

Journal Articles

The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Blood (2019) 134 (Supplement_1): 1642.

https://doi.org/10.1182/blood-2019-130148

Published: 2019

Journal Articles

RNA Sequencing-Based Measurement of Fusion-Transcript for Minimal Residual Disease (MRD) Monitoring in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Taehyung Kim, MSc, Joon Ho Moon, MD, Jae-Sook Ahn, MD PhD, Marc S. Tyndel, B. Eng, Seung-Shin Lee, MD, Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Deok-Hwan Yang, MD PhD, Je-Jung Lee, MD PhD, Seunghyun Choi, PhD, Ja-yeon Lee, MSc, Yoojin Lee, MDPhD, Sang Kyun Sohn, MD PhD, Zhaolei Zhang, PhD, Hyeoung-Joon Kim, MD PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 2669.

https://doi.org/10.1182/blood-2018-99-112037

Published: 2018

Journal Articles

A Novel Predictor of Response to Gemtuzumab Ozogamicin Therapy in AML Provides Strategies for Sensitization of Leukemia Stem Cells in Individual Patients

Stanley W.K. Ng, Schoof E Erwin, Amanda Mitchell, PhD, Mark D. Minden, MD PhD, Lars Bullinger, MD, Hartmut Döhner, MD, Hervé Dombret, Claude Preudhomme, Meyling Cheok, BSPharm, PhD, John E. Dick, PhD, Jean C.Y. Wang, MD PhD

Blood (2018) 132 (Supplement 1): 2765.

https://doi.org/10.1182/blood-2018-99-114275

Published: 2018

Journal Articles

Deep Immunoprofiling of the Bone Marrow Microenvironmental Changes Underlying the Multistep Progression of Multiple Myeloma

Mary H Young, PhD, Sam A Danziger, Alison Fitch, Frank Schmitz, MD PhD, Jake Gockley, PhD, Mark McConnell, PhD, David Reiss, PhD, Wilbert B. Copeland, PhD, Sarah K Johnson, PhD, Katie Newhall, PhD, Robert Hershberg, MD PhD, Teri Foy, PhD, Alexander Ratushny, PhD, Brian A Walker, PhD, Andrew Dervan, Gareth Morgan, MD

Blood (2018) 132 (Supplement 1): 243.

https://doi.org/10.1182/blood-2018-99-113042

Published: 2018

Journal Articles

Prediction of Leukemia-Free Survival Following Haploidentical Stem Cell Transplantation in Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Roni Shouval, MD PhD, Joshua A Fein, Myriam Labopin, MD, Fabio Ciceri, MD, Emanuele Angelucci, MD, Didier Blaise, Johanna Tischer, William Arcese, Koc Yener, MD, Benedetto Bruno, José Luís Díez Martín, MD, Stella Santarone, MD, Simona Sica, MD, Mohamad Mohty, MD PhD, Arnon Nagler, MD

Blood (2018) 132 (Supplement 1): 485.

https://doi.org/10.1182/blood-2018-99-111822

Published: 2018

Journal Articles

Model of the Impact of Delayed Inhibitor Development on Cumulative Breakthrough Bleeds and Costs in Persons with Hemophilia A Receiving Emicizumab Prophylaxis

Robert F. Sidonio, Jr., Anisha Patel, Shelby Corman, Stephen Chaplin, Karina Raimundo

Blood (2018) 132 (Supplement 1): 4710.

https://doi.org/10.1182/blood-2018-99-116410

Published: 2018

NARROW

Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients

Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome

US Optum Database Study in Polycythemia Vera Patients: Thromboembolic Events (TEs) with Hydroxyurea (HU) Vs Ruxolitinib Switch Therapy and Machine-Learning Model to Predict Incidence of Tes and HU Failure

Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)

Supervised Machine Learning Algorithms Using Patient Related Factors to Predict in-Hospital Mortality Following Acute Myeloid Leukemia Therapy

Cost-Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease

BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Beyond the Routine CBC: Research CBC Parameters Associated with Myelodysplastic Syndromes and Underlying Mutations

Dasatinib and Nilotinib As Upfront Therapy for Chronic-Phase Chronic Myeloid Leukemia (CML-CP) in Qatar: A Cost Effectiveness Analysis (CEA)

Is It Time to Take MRD More Seriously? Relationship between MRD, Functional Cure and Life Expectancy Among Patients with Ph- B Cell Precursor ALL (BCP-ALL)

Use of Machine Learning in 2074 Cases of Acute Myeloid Leukemia for Genetic Risk Profiling

Dasatinib Inhibits FLT3 /ITD and PTPN11 mutated Acute Myeloid Leukemia Cells Overexpressing SRC Tyrosine Kinases

The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

RNA Sequencing-Based Measurement of Fusion-Transcript for Minimal Residual Disease (MRD) Monitoring in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

A Novel Predictor of Response to Gemtuzumab Ozogamicin Therapy in AML Provides Strategies for Sensitization of Leukemia Stem Cells in Individual Patients

Deep Immunoprofiling of the Bone Marrow Microenvironmental Changes Underlying the Multistep Progression of Multiple Myeloma

Prediction of Leukemia-Free Survival Following Haploidentical Stem Cell Transplantation in Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Model of the Impact of Delayed Inhibitor Development on Cumulative Breakthrough Bleeds and Costs in Persons with Hemophilia A Receiving Emicizumab Prophylaxis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only